Dong Wang

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Gene Expression

Epithelial Mesenchymal Transition

Top Venues

Molecules (Basel, Switzerland)

Science advances

Molecular cancer therapeutics

Cancer biology & medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yan Luo, Guochen Zhang, Chao Hu, Lijun Huang, Dong Wang, Zhejie Chen, Yumei Wang
The Role of Natural Products from Herbal Medicine in TLR4 Signaling for Colorectal Cancer Treatment. Molecules (Basel, Switzerland) 29 (12) (2024)
Yan Luo, Guochen Zhang, Chao Hu, Lijun Huang, Dong Wang, Zhejie Chen, Yumei Wang
The Role of Natural Products from Herbal Medicine in TLR4 Signaling for Colorectal Cancer Treatment. Molecules (Basel, Switzerland) 29 (12) (2024)
Yan Luo, Guochen Zhang, Chao Hu, Lijun Huang, Dong Wang, Zhejie Chen, Yumei Wang
The Role of Natural Products from Herbal Medicine in TLR4 Signaling for Colorectal Cancer Treatment. Molecules (Basel, Switzerland) 29 (12) (2024)
Yumei Wang, Haiyan Wang, Wei Shao, Yuhui Chen, Yu Gui, Chao Hu, Xiaohong Yi, Lijun Huang, Shasha Li, Dong Wang
Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer. Cancer biology & medicine (2023)
Liuqing Yang, Kequan Lin, Lin Zhu, Huili Wang, Shuaishuai Teng, Lijun Huang, Shiyi Zhou, Guanbin Zhang, Zhi John Lu, Dong Wang
Long non-coding RNA DARS-AS1 promotes tumor progression by directly suppressing PACT-mediated cellular stress. Communications biology 5 (1) (2022)
Peng Peng, Xiaoyan Qiang, Guoyu Li, Lin Li, Shumao Ni, Qi Yu, Laura Sourd, Elisabetta Marangoni, Chao Hu, Dong Wang, Di Wu, Frank Wu
Tinengotinib (TT-00420), a Novel Spectrum-Selective Small Molecule Kinase Inhibitor, Is Highly Active Against Triple Negative Breast Cancer. Molecular cancer therapeutics (2022)
Haiyan Wang, Shasha Li, Qianyu Wang, Zhengshuo Jin, Wei Shao, Yan Gao, Lu Li, Kequan Lin, Lin Zhu, Huili Wang, Xuebin Liao, Dong Wang
Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds. Science advances 7 (4) (2021)